FDA approves groundbreaking new drug for pancreatic cancer
The Food and Drug Administration approved a groundbreaking new oral drug for pancreatic patients suffering from the most aggressive form of the disease. Daraxonrasib, which targets a mutation in a gene called KRAS, doubled the survival time in patients who participated in the trial.
NBC News3 sources
First coverage · Latest coverage
Compiled by CurrentWire News Desk
Summary based on reporting from The Hill, NBC News and STAT.
Coverage at a glance
- First observed by CurrentWire: STAT · Aug 26, 2026 at 10:56 AM ET
- Coverage span: 3h 0m
- Coverage: 4 reports from 3 independent publications
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
4 reports from 3 publications.
Excerpts are the summaries each publisher distributes with its own feed, shortened and attributed.
NBC NewsTier B
FDA approves groundbreaking new drug for pancreatic cancer(opens original report in a new tab)NBC NewsTier B
FDA approves ‘game-changing’ pancreatic cancer drug(opens original report in a new tab)The Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease. — NBC News
The HillTier B
FDA approves groundbreaking new pancreatic cancer drug(opens original report in a new tab)The Food and Drug Administration (FDA) on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer. The once-daily… — The Hill
STATTier B
STAT+: FDA approves new pancreatic cancer drug expected to usher in new era of treatment(opens original report in a new tab)The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy. — STAT
How coverage developed
First report from STAT
Reported by The Hill
Reported by NBC News
Reported by NBC News
How CurrentWire compiled this story
NBC News (www.nbcnews.com), a Tier B publisher, filed this report on .
Signal breakdown
CurrentWire ranked this story 78.4 of 100 in the snapshot this page was rendered from.
- Freshness
- 30.4 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 11.1 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 8 of 10
- Velocity
- 5 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Health · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.